Emily M. Leproust, serving as both Chief Executive Officer and a Director at Twist Bioscience Corp (NASDAQ:TWST), has completed a substantial disposition of company equity. On June 25, 2026, Leproust sold a total of 18,880 shares of common stock, generating proceeds of $1,793,600. The transaction was executed at a price of $95.00 per share. This specific sale was facilitated through a Rule 10b5-1 trading plan, a standardized framework for executives to manage stock transactions without the appearance of insider trading. Leproust originally established this particular trading plan on May 27, 2025, setting the parameters for the recent divestment.
The timing of this executive sale coincides with a period of significant valuation expansion for Twist Bioscience. As of the transaction date, TWST shares were trading at $99.84, a level hovering near its 52-week high of $98.40. The stock has experienced a dramatic appreciation of 205% year-to-date, a performance metric that has contributed to the company achieving a market capitalization of $6.21 billion. Despite this robust market performance, data from InvestingPro analysis suggests that the stock may be trading at a premium relative to its intrinsic worth. The analysis places TWST on the "Most Overvalued" list, indicating a divergence between current market pricing and fair value assessments. For investors seeking to understand the valuation gap, comprehensive Pro Research Reports are available, including detailed coverage of TWST among over 1,400 reports.
Following the execution of this sale, Leproust's direct ownership stake in Twist Bioscience stands at 824,039 shares. The regulatory filing associated with this transaction also provided a detailed inventory of her employee stock options. These options carry exercise prices ranging from a low of $5.95 to a high of $67.85, with expiration dates extending through September 2030. The vesting schedules for these options are varied, including performance-based options that were already vested in December 2022, highlighting the long-term incentive structure tied to her role.
The executive transaction occurs amidst a wave of positive analyst coverage and financial updates for the biotechnology sector. Twist BiosScience reported second-quarter revenues of $111 million, representing a 19% year-over-year growth rate. This financial result surpassed the consensus estimate of $108 million, providing a fundamental catalyst for analyst revisions. Following this revenue beat, TD Cowen upgraded its price target from $58 to $68, maintaining a Buy rating on the stock. Subsequently, TD Cowen further increased its price target to $89, citing the company's strategic positioning to address the escalating demand for wet lab capabilities and data processing driven by artificial intelligence applications.
Additional analyst activity reinforces the optimistic outlook for the sector. Canaccord Genuity initiated coverage on Twist Bioscience with a Buy rating and a $90 price target, specifically highlighting the utility of the company's proprietary silicon-based lab-on-a-chip technology. Similarly, Piper Sandler initiated coverage with an Overweight rating and an $85 price target, emphasizing the scalability of Twist's DNA synthesis platform in the context of expanding AI applications within biology. Leerink also raised its price target to $80 from $70, maintaining an Outperform rating following insights shared during the company's Investor Day. During this event, management outlined ambitious financial projections, expecting revenue to reach approximately $1 billion by fiscal year 2031, which implies a compound annual growth rate of over 16%.
Market data indicates TWST closed at $99.84, reflecting a gain of $3.19 or 3.30%. After-hours trading showed a slight consolidation at $99.75, down $0.09 or 0.09%. The stock's trajectory from its 52-week high of $98.40 to its current trading level of $99.84 underscores the intense investor interest in the intersection of biotechnology and artificial intelligence. The company's ability to scale its DNA synthesis platform and leverage silicon-based technology positions it as a key player in the wet lab data infrastructure space. However, the divergence between the stock's market capitalization of $6.21 billion and the "Most Overvalued" classification from InvestingPro suggests that investors must carefully weigh the high growth expectations against current valuation metrics. The reliance on AI-driven demand and the execution of the $1 billion revenue target by 2031 remain critical factors for sustaining the current valuation multiples.